The FDA approved Eli Lilly’s tirzepatide (Mounjaro) to reduce cardiovascular risk in adults with type 2 diabetes at high risk for events. The approval is based on SURPASS-CVOT, a head-to-head cardiovascular outcomes trial comparing tirzepatide with dulaglutide. Lilly reported an 8% lower rate of major adverse cardiovascular events versus dulaglutide (MACE-3) with a hazard ratio of 0.92, alongside a generally consistent tolerability profile with prior tirzepatide experience. The decision expands tirzepatide’s label beyond glycemic control and weight reduction. For biotech and payers, the move reinforces the centrality of cardiometabolic outcomes trials in securing new premium positioning for incretin-based medicines.